Bambusa Therapeutics

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1/2
IL-4Ralpha / IL-5Multispecific antibody
Chronic Obstructive Pulmonary Disease
Phase 1
IL-4Rα and IL-31Multispecific antibody
Atopic Dermatitis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
December 2027 (2)
BBT001Phase 1/2Chronic Spontaneous Urticaria
Est. primary completion 2027-12-31 · NCT07717905 · CT.gov ↗
What to watch
BBT002Phase 1/2Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Est. primary completion 2027-12-31 · NCT07436949 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.